PURPOSE OF INVESTIGATION: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). METHODS: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. RESULTS: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. CONCLUSIONS: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.
PURPOSE OF INVESTIGATION: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). METHODS: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. RESULTS: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. CONCLUSIONS: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.
Authors: Alexia Iasonos; Paul Sabbatini; David R Spriggs; Carol A Aghajanian; Roisin E O'Cearbhaill; Martee L Hensley; Howard T Thaler Journal: Int J Gynecol Cancer Date: 2012-01 Impact factor: 3.437
Authors: Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood Journal: Cancer Metastasis Rev Date: 2015-03 Impact factor: 9.264
Authors: Elizabeth V Connor; Caner Saygin; Chad Braley; Andrew C Wiechert; Sheelarani Karunanithi; Katie Crean-Tate; Fadi W Abdul-Karim; Chad M Michener; Peter G Rose; Justin D Lathia; Ofer Reizes Journal: J Ovarian Res Date: 2019-11-17 Impact factor: 4.234